{"id":"marketed-pramipexole-er","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dizziness"},{"rate":"10-20","effect":"Somnolence"},{"rate":"5-15","effect":"Hallucinations"},{"rate":"10-15","effect":"Orthostatic hypotension"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Constipation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pramipexole binds to and activates dopamine D2 and D3 receptors, particularly in the striatum and other basal ganglia structures. By mimicking dopamine's action, it compensates for the loss of dopamine-producing neurons characteristic of Parkinson's disease, thereby improving motor symptoms such as tremor, rigidity, and bradykinesia. The extended-release formulation allows for once-daily dosing with more stable plasma levels compared to immediate-release formulations.","oneSentence":"Pramipexole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to improve motor control and reduce symptoms of Parkinson's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:10.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (motor symptoms)"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT03329508","phase":"PHASE3","title":"A Phase 3 Study With P2B001 in Subjects With Early Parkinson's","status":"COMPLETED","sponsor":"Pharma Two B Ltd.","startDate":"2018-01-19","conditions":"Parkinson Disease, Early Parkinson's Disease","enrollment":544}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PramiER"],"phase":"phase_3","status":"active","brandName":"Marketed Pramipexole ER","genericName":"Marketed Pramipexole ER","companyName":"Pharma Two B Ltd.","companyId":"pharma-two-b-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pramipexole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to improve motor control and reduce symptoms of Parkinson's disease. Used for Parkinson's disease (motor symptoms), Restless legs syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}